Canaccord Genuity analyst William Plovanic has maintained their neutral stance on EW stock, giving a Hold rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
William Plovanic has given his Hold rating due to a combination of factors surrounding Edwards Lifesciences’ future growth prospects and current financial guidance. The company recently hosted its annual investor day, where it provided its initial guidance for 2026, which appears achievable. Despite the company’s bottom-line growth outpacing the top line and significant investments in R&D, the anticipated growth catalysts are expected to materialize more significantly in the latter half of 2026. This back-end-loaded growth expectation contributes to the Hold rating.
Plovanic acknowledges that there are more favorable factors than challenges for Edwards Lifesciences, yet the reliance on better-than-expected execution for upside potential in 2026 numbers warrants a cautious approach. The reaffirmation of FY2025 guidance and the initial 2026 guidance align with consensus expectations, projecting modest sales and EPS growth. Adjustments to revenue and EPS estimates reflect these projections, leading to a maintained Hold rating with a slight increase in the price target from $84 to $89.
Plovanic covers the Healthcare sector, focusing on stocks such as Insulet, TransMedics Group, and Boston Scientific. According to TipRanks, Plovanic has an average return of 2.9% and a 44.78% success rate on recommended stocks.